| |
Cell and gene therapies for rare diseases often present unique obstacles that can be overcome using in silico approaches. Learn how in our on-demand webinar, and meet us at BIO to discuss how Premier Consulting can advance your CGT program to its next milestone. Premier Consulting. Built for Biotech℠. _updated.png)
|
|
Today's Big NewsMay 25, 2023 |
Mirati's long wait for next lung cancer med ends in phase 3 failure
Annexon's eye disease med improved vision in a phase 2 trial but flunked the primary goal. The CEO was thrilled
BenevolentAI makes deep cuts after midphase flop, laying off 180 and shrinking lab footprint
PD-1 inhibitor R&D tapering off as newer oncology molecules capture attention: IQVIA
Fierce Biotech Fundraising Tracker '23: VarmX tacks on series B2 funds; ElevateBio steals ReNAgade's fundraise crown with $401M haul |
|
July 18-19, 2023 | Jersey City, NJ More panels and case studies providing real, practical experiences and solutions, including topics surrounding Investor Relations and Government Affairs. Save $500 when you Register before May 30th!
|
|
| By Annalee Armstrong After a five and a half month wait, Mirati Therapeutics finally has the answer it’s been waiting for on a lung cancer med called sitravatinib. The therapy didn't work. |
|
|
|
| San Diego, CA |  |
|
|
By Max Bayer Annexon's geographic atrophy treatment failed to improve lesion growth in a phase 2 trial but did improve vision, which the CEO thinks will support a late-stage study. |
By Nick Paul Taylor BenevolentAI is cutting back its drug development operation in the wake of a midphase flop, laying off up to 180 staff, reducing its lab footprint, pausing some programs and dropping its lead candidate. |
By James Waldron Move over PD-1, your time has passed. At least, that’s the sense from IQVIA’s latest report, which suggests development of immuno-oncologics such as PD-1/PD-L1 checkpoint inhibitors has started to “taper off." |
|
Explore the whole transcriptome with a prep that generates libraries in under 4.5 hours - including rRNA depletion - and delivers superior gene detection sensitivity with FFPE and low inputs. View the Data. .png)
|
|
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Joseph Keenan Decentralized clinical trial tech company THREAD signed on with Allucent to launch a new services platform directed at small and emerging biotech companies navigating their way through remote trials. |
By Joseph Keenan Veeva Systems, which provides cloud-based healthcare software, inked a deal with the biopharma UCB aimed at improving the patient experience in digital clinical trials. |
By Andrea Park Though the smallest of Medtronic’s four core businesses, the diabetes department has taken center stage as of late. |
By Kevin Dunleavy Many employees at pharma companies find their work exhausting and are susceptible to burnout, according to a new report from workplace culture expert O.C. Tanner Institute. Among nearly 300 surveyed employees, 48% reported finding their work exhausting, with 30% feeling emotionally frustrated. |
By Heather Landi Large language models like ChatGPT and Microsot's Azure OpenAI service have only been available to the public for a few months, but tech leaders at a handful of health systems are eager to test-drive the tech. |
By Zoey Becker The companies must defend themselves against claims that they colluded to prevent generics to Gilead's HIV meds from entering the market. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we''ll discuss the recent biopharma layoff trends, plus Elizabeth Holmes, Sarepta Therapeutics, Abbott's FDA approval, and the rest of the week's headlines. |
|
|---|
|
|
Whitepaper ChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
eBook Discover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
Whitepaper This paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Research Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
Whitepaper For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
